Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sanja Sever
Rush University Medical Center, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Trisaq, Inc
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Sever is a co-founder of Trisaq, a company focused on developing products to eliminate or modulate molecular targets that are responsible for the destruction of the kidney's podocytes and for the deterioration of the kidneys' filtering function. The goal of this grant is to identify novel hits that protect podocytes from damage. The company could therefore have an interest in the results of the research. Based on the magnitude of Dr. Sever’s financial interest in Trisaq and the close connection between the company’s interests and the research, the Partners Committee on Outside Activities (COA) review panel determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Novel Anti-Proteinuric Strategies Targeting Podocytes
Project Narrative Proteinuria is one of the earliest signs of kidney disease and often leads to end stage renal disease (ESRD), which has limited treatment options. Novel, targeted therapeutics to better protect the cells that constitute the kidney filter, the podocytes, and that can be tailored for patients with different underlying causes of proteinuric kidney disease are urgently needed. The studies proposed here are expected to provide novel drug candidates for development into such therapeutics in the near future.
Filed on March 01, 2017.
Tell us what you know about Sanja Sever's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Sanja Sever”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Sanja Sever | Massachusetts General Hospital | Conflict of Interest | Trisaq, Inc. | Value cannot be readily determined |
| Sanja Sever | Massachusetts General Hospital | Conflict of Interest | Trisaq, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.